Chinese vaccine company, Jiangsu Recbio Technology Co., Ltd., announced receiving clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, from the Food and Drug Administration of the Philippines.
The study will evaluate the safety and immunogenicity of REC610 in healthy adult subjects aged 40 and above.
Shingles is an acute infectious skin disease caused by reactivation of latent varicella zoster virus (VZV) in the body. There is no specific medicine for shingles, and vaccine is an effective means of preventing shingles. According to research data on shingles vaccines that have been marketed around the world, the novel adjuvanted vaccine can provide stronger cellular immunity and protective efficacy as compared to live attenuated vaccines.
REC610 is equipped with a novel adjuvant BFA01 independently developed by the Company, which can promote the production of
high levels of VZV glycoprotein E (gE)-specific CD4+ T cells and antibody. Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE-specific CD4+T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix®.
- CDC warns of Salmonella infections linked to raw alfalfa sprouts
- Vietnam: Phú Thọ man dies from rabies months after dog bite
- Malaysia advises public how to avoid Naegleria fowleri after South Korea reports 1st case
- Nebraska reports Salmonella outbreak, Linked to alfalfa sprouts
- South Africa reports 13th confirmed human rabies case of 2022
- Plague deaths reported in Ambohidratrimo district: Madagascar media
- West Nile virus case reported in Hillsborough County
- Dengue in Miami-Dade County: Four additional locally acquired cases reported